Home › Products › Oncology › LetroSYM 2.5 Tablet
LetroSYM 2.5 Tablet
Salt Composition: LETROZOLE
- Manufacturer: SYMBION LIFE SCIENCE
- Pack Size: 10 TABLET(s) IN A STRIP
- Dosage Form: TABLET
- Strength: 2.5MG
- Prescription Required
- Storage: Keep the tablets away from the reach of children and pets. Store LetroSYM 2.5 Tablet at an optimal temperature not exceeding 25°C.
₹180.00₹300.00
Inclusive of all taxes
Product Introduction
LetroSYM 2.5 Tablet is an anti-cancer medication belonging to the aromatase inhibitor class. It is indicated as adjuvant therapy following primary treatment, or as first-line therapy, for postmenopausal women with early and advanced breast cancer whose tumours are hormone receptor-positive. Since elevated oestrogen levels are associated with breast cancer development, this medicine reduces female reproductive hormone levels by inhibiting the aromatase enzyme responsible for oestrogen synthesis. The medication aims to slow or arrest tumour growth and prevent spread to other body sites. Inform your physician if you have not reached menopause, as this medicine is ineffective in premenopausal women. Because this medicine lowers female reproductive hormone levels, it is not suitable for menstruating women due to associations with fertility complications. Monitor your cholesterol levels regularly, as this medicine may elevate them. This medicine may also decrease bone mineral density; discuss with your physician and consider regular monitoring of bone parameters. Effective contraception is advised during treatment and for at least 3 weeks after the final dose.
Uses
First and second-line treatment of postmenopausal women with hormone receptor-positive breast cancer. Supportive to standard treatment for postmenopausal women with early breast cancer. Treatment for unknown advanced breast cancer in postmenopausal women. Extended supportive therapy for postmenopausal women with early breast cancer who have already taken other anti-cancer medication.
How it works
The growth of some cancers of breasts are stimulated by estrogens. LetroSYM 2.5 Tablet is a nonsteroidal compound that inhibits estrogen production by blocking the enzyme aromatase. This medicine reduces the tumor size and stops or slows the progression of the disease, avoiding the reoccurring of early-stage breast cancer and improving the survival rate.
How to Use
It is advised to consume LetroSYM 2.5 Tablet exactly as your doctor prescribes. It can be consumed with or without food and should be swallowed with a glass of water. LetroSYM 2.5 Tablet can be taken with or without food. It is better to take the tablet at a fixed time. Do not break, chew or crush the tablet.
Side Effects
Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them. Serious Decreased red blood cells Decreased bone mineral density Fluid buildup in lungs Common Swelling in the face, eyes, feet, and legs Hot sweats and excessive sweating Hypercholesterolemia (high cholesterol) Constipation Heart papilation Hypertension Diarrhea Loss of appetite Nausea and Vomiting Muscle pain, bone pain, and joint stiffness Dizziness, tiredness, and sleepiness Breathing difficulty Arthralgia
References
- Ranbaxy (UK) Limited a Sun Pharmaceutical Company, [Revised on December 2022], [Accessed on January 2024], https://www.medicines.org.uk/emc/files/pil.9722.pdf
- Novartis Pharmaceuticals Corporation, [Revised on May 2020], [Accessed on 22th Mar 2023], https://www.novartis.com/us-en/sites/novartis_us/files/Femara.pdf?TB_iframe=true
- HIGHLIGHTS OF PRESCRIBING INFORMATION. (n.d.). [online] www.accessdata.fda.gov. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020726s027lbl.pdf [Accessed on 22th Mar 2023].
- Edward Chu, Cancer Chemotherapy, Lange’s Basic and Clinical Pharmacology, 14th Edition, 2018, 948-976.
- KD Tripathi, Estrogens, Progestins and Contraceptives, Essentials of Medical Pharmacology, 8th Edition, 2019, 330-353.
Safety Advice
Pregnancy: Unsafe LetroSYM 2.5 Tablet are highly unsafe during pregnancy because they may cause harm to the unborn baby. It is better to discuss with a doctor the use of an effective contraceptive method during the LetroSYM 2.5 Tablet treatment if you still have the potential to become pregnant. It is recommended to consult your physician if you are pregnant already or suspect pregnancy.
Lungs: Consult Your Doctor Certain lung diseases can occur while using LetroSYM 2.5 Tablet. Consult your doctor if you have lung diseases.
Breastfeeding: Unsafe It is not safe to breastfeed your baby when you are taking a LetroSYM 2.5 Tablet. It is advised to avoid breastfeeding for at least three weeks after the last dose of the medicine.
Disclaimer
The information provided on this page is intended for general informational purposes only and should not be considered as medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication. Self-medication can be harmful. Med For Rare does not endorse self-diagnosis or self-treatment.